JP2006506977A5 - - Google Patents

Info

Publication number

JP2006506977A5

JP2006506977A5 JP2004529382A JP2004529382A JP2006506977A5 JP 2006506977 A5 JP2006506977 A5 JP 2006506977A5 JP 2004529382 A JP2004529382 A JP 2004529382A JP 2004529382 A JP2004529382 A JP 2004529382A JP 2006506977 A5 JP2006506977 A5 JP 2006506977A5

Authority

JP

Japan

Prior art keywords

antibody

binds

fcγriib

fragment

fcγriia

Prior art date

2003-08-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 40
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 40
• 239000012634 fragment Substances 0.000 claims 37
• 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 25
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 25
• 206010028980 Neoplasm Diseases 0.000 claims 23
• 201000011510 cancer Diseases 0.000 claims 18
• 239000003814 drug Substances 0.000 claims 15
• 238000004519 manufacturing process Methods 0.000 claims 13
• 239000000427 antigen Substances 0.000 claims 12
• 102000036639 antigens Human genes 0.000 claims 12
• 108091007433 antigens Proteins 0.000 claims 12
• 230000000694 effects Effects 0.000 claims 9
• 102000039446 nucleic acids Human genes 0.000 claims 9
• 108020004707 nucleic acids Proteins 0.000 claims 9
• 150000007523 nucleic acids Chemical class 0.000 claims 9
• 230000007783 downstream signaling Effects 0.000 claims 8
• 210000004408 hybridoma Anatomy 0.000 claims 8
• 231100000433 cytotoxic Toxicity 0.000 claims 7
• 230000001472 cytotoxic effect Effects 0.000 claims 7
• 230000028993 immune response Effects 0.000 claims 7
• 238000000034 method Methods 0.000 claims 7
• -1 Btk Proteins 0.000 claims 6
• 210000004027 cell Anatomy 0.000 claims 6
• 239000008194 pharmaceutical composition Substances 0.000 claims 6
• 210000003719 b-lymphocyte Anatomy 0.000 claims 5
• 230000019491 signal transduction Effects 0.000 claims 5
• 208000023275 Autoimmune disease Diseases 0.000 claims 4
• 241000699666 Mus <mouse, genus> Species 0.000 claims 4
• 230000001404 mediated effect Effects 0.000 claims 4
• 238000011282 treatment Methods 0.000 claims 4
• 239000013598 vector Substances 0.000 claims 4
• 239000002246 antineoplastic agent Substances 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 229940079593 drug Drugs 0.000 claims 3
• 230000002163 immunogen Effects 0.000 claims 3
• 210000002540 macrophage Anatomy 0.000 claims 3
• 239000000203 mixture Substances 0.000 claims 3
• 229920001184 polypeptide Polymers 0.000 claims 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims 3
• 229960005486 vaccine Drugs 0.000 claims 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
• 108091008875 B cell receptors Proteins 0.000 claims 2
• 206010006187 Breast cancer Diseases 0.000 claims 2
• 208000026310 Breast neoplasm Diseases 0.000 claims 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
• 102000043136 MAP kinase family Human genes 0.000 claims 2
• 108091054455 MAP kinase family Proteins 0.000 claims 2
• 241000699660 Mus musculus Species 0.000 claims 2
• 206010033128 Ovarian cancer Diseases 0.000 claims 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
• 206010060862 Prostate cancer Diseases 0.000 claims 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
• 230000004913 activation Effects 0.000 claims 2
• 230000000172 allergic effect Effects 0.000 claims 2
• 229940041181 antineoplastic drug Drugs 0.000 claims 2
• 208000010668 atopic eczema Diseases 0.000 claims 2
• PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims 2
• 229950010231 brequinar Drugs 0.000 claims 2
• 230000009460 calcium influx Effects 0.000 claims 2
• 230000020411 cell activation Effects 0.000 claims 2
• 230000004663 cell proliferation Effects 0.000 claims 2
• 201000010881 cervical cancer Diseases 0.000 claims 2
• 229960004397 cyclophosphamide Drugs 0.000 claims 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims 2
• 239000002619 cytotoxin Substances 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 210000002950 fibroblast Anatomy 0.000 claims 2
• 210000003630 histaminocyte Anatomy 0.000 claims 2
• 238000001794 hormone therapy Methods 0.000 claims 2
• 230000003053 immunization Effects 0.000 claims 2
• 230000016784 immunoglobulin production Effects 0.000 claims 2
• 238000009169 immunotherapy Methods 0.000 claims 2
• 230000003834 intracellular effect Effects 0.000 claims 2
• 230000036210 malignancy Effects 0.000 claims 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
• 239000003550 marker Substances 0.000 claims 2
• 239000003607 modifier Substances 0.000 claims 2
• 229940126619 mouse monoclonal antibody Drugs 0.000 claims 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
• 201000002528 pancreatic cancer Diseases 0.000 claims 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
• 230000026731 phosphorylation Effects 0.000 claims 2
• 238000006366 phosphorylation reaction Methods 0.000 claims 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
• 238000001959 radiotherapy Methods 0.000 claims 2
• 230000007115 recruitment Effects 0.000 claims 2
• 238000012216 screening Methods 0.000 claims 2
• 150000003431 steroids Chemical class 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• 238000011830 transgenic mouse model Methods 0.000 claims 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
• 230000003844 B-cell-activation Effects 0.000 claims 1
• 102000015735 Beta-catenin Human genes 0.000 claims 1
• 108060000903 Beta-catenin Proteins 0.000 claims 1
• 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
• 206010010741 Conjunctivitis Diseases 0.000 claims 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 229930105110 Cyclosporin A Natural products 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• 101710112752 Cytotoxin Proteins 0.000 claims 1
• 108010092160 Dactinomycin Proteins 0.000 claims 1
• 206010014950 Eosinophilia Diseases 0.000 claims 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
• 102100039717 G antigen 1 Human genes 0.000 claims 1
• 206010018364 Glomerulonephritis Diseases 0.000 claims 1
• 108010026389 Gramicidin Proteins 0.000 claims 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
• 241000701806 Human papillomavirus Species 0.000 claims 1
• 241000701603 Human papillomavirus type 52 Species 0.000 claims 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
• 229930192392 Mitomycin Natural products 0.000 claims 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims 1
• 102100034256 Mucin-1 Human genes 0.000 claims 1
• 108010008707 Mucin-1 Proteins 0.000 claims 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
• 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
• 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
• 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims 1
• 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• 102000001253 Protein Kinase Human genes 0.000 claims 1
• 201000004681 Psoriasis Diseases 0.000 claims 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
• 208000033464 Reiter syndrome Diseases 0.000 claims 1
• 206010039085 Rhinitis allergic Diseases 0.000 claims 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 claims 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
• 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
• 230000001919 adrenal effect Effects 0.000 claims 1
• 201000010105 allergic rhinitis Diseases 0.000 claims 1
• 239000002260 anti-inflammatory agent Substances 0.000 claims 1
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
• 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 239000012472 biological sample Substances 0.000 claims 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical group O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 claims 1
• 229940112129 campath Drugs 0.000 claims 1
• 230000022534 cell killing Effects 0.000 claims 1
• 230000036755 cellular response Effects 0.000 claims 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 229940044683 chemotherapy drug Drugs 0.000 claims 1
• 229960001338 colchicine Drugs 0.000 claims 1
• 230000001054 cortical effect Effects 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 claims 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 claims 1
• 229960000640 dactinomycin Drugs 0.000 claims 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
• 229960000975 daunorubicin Drugs 0.000 claims 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 229960001259 diclofenac Drugs 0.000 claims 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 238000002651 drug therapy Methods 0.000 claims 1
• 239000012636 effector Substances 0.000 claims 1
• 230000002708 enhancing effect Effects 0.000 claims 1
• 230000002255 enzymatic effect Effects 0.000 claims 1
• 229960001904 epirubicin Drugs 0.000 claims 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims 1
• 229960005542 ethidium bromide Drugs 0.000 claims 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
• 229960005420 etoposide Drugs 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 201000005298 gastrointestinal allergy Diseases 0.000 claims 1
• 239000003862 glucocorticoid Substances 0.000 claims 1
• 239000001963 growth medium Substances 0.000 claims 1
• 229940022353 herceptin Drugs 0.000 claims 1
• 229960001680 ibuprofen Drugs 0.000 claims 1
• 230000008595 infiltration Effects 0.000 claims 1
• 238000001764 infiltration Methods 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 229960000681 leflunomide Drugs 0.000 claims 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
• 229960004194 lidocaine Drugs 0.000 claims 1
• 206010025135 lupus erythematosus Diseases 0.000 claims 1
• 239000002609 medium Substances 0.000 claims 1
• 102000006240 membrane receptors Human genes 0.000 claims 1
• 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• 229960004857 mitomycin Drugs 0.000 claims 1
• 229960001156 mitoxantrone Drugs 0.000 claims 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
• 229950000844 mizoribine Drugs 0.000 claims 1
• 230000004048 modification Effects 0.000 claims 1
• 238000012986 modification Methods 0.000 claims 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
• 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
• 229960002009 naproxen Drugs 0.000 claims 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• 230000016833 positive regulation of signal transduction Effects 0.000 claims 1
• 229960004919 procaine Drugs 0.000 claims 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
• 229960003712 propranolol Drugs 0.000 claims 1
• 108060006633 protein kinase Proteins 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 229950010131 puromycin Drugs 0.000 claims 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
• 208000002574 reactive arthritis Diseases 0.000 claims 1
• 230000006798 recombination Effects 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 229960004641 rituximab Drugs 0.000 claims 1
• 229960002930 sirolimus Drugs 0.000 claims 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
• 210000004989 spleen cell Anatomy 0.000 claims 1
• 210000004988 splenocyte Anatomy 0.000 claims 1
• 210000002536 stromal cell Anatomy 0.000 claims 1
• 230000001629 suppression Effects 0.000 claims 1
• 238000001356 surgical procedure Methods 0.000 claims 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
• 229960001278 teniposide Drugs 0.000 claims 1
• 229960002372 tetracaine Drugs 0.000 claims 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 210000004881 tumor cell Anatomy 0.000 claims 1
• 229960003048 vinblastine Drugs 0.000 claims 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
• 229960004528 vincristine Drugs 0.000 claims 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1